LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E0073

    Ebselen

    Synthetic glutathione peroxidase mimetic; yeast...

    ≥99%
  • M5877

    Motesanib Diphosphate

    VEGFR, PDGFR, c-Kit, RET inhibitor.

    ≥98%
  • V9200

    VX-950

    NS3/4A serine protease inhibitor.

    ≥98%
  • V3479

    Vitamin K3

    Synthetic analog of 1,4-naphthoquinone, precurs...

    ≥98%
  • M568266

    Mogroside IIIe

    Triterpenoid

    ≥98%
  • G880000

    GW 405833

    Cannabinoid receptor 2 selective agonist.

    ≥98%
  • L1782

    Levodopa

    Endogenous catecholamine precursor, also found ...

    ≥98%
  • B1973

    Besifloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • B0025

    Bafilomycin A1

    Macrolide antibiotic; vacuolar H+ ATPase inhibi...

    ≥90%
  • S6800

    SR1001

    RORα/γ inverse agonist.

    ≥99%
  • A016495

    5-Aminopyrimidine

    Building block

    ≥98%
  • A5070

    Angiotensin Acetate

    Peptide, derivative of AT I, cleavage product o...

    ≥95%
  • F4680

    Flutamide

    Non-steroid; AR antagonist.

    ≥98%
  • A851322

    Avibactam Sodium

    Diazabicyclooctane β-lactamase inhibitor.

    ≥98%
  • E846182

    Everolimus EP Impurity E

    Impurity of everolimus

    ≥80%
  • S1606

    Secretin, porcine

    Endogenous peptide hormone, involved in water h...

    ≥95%
  • F0275

    Fasudil Hydrochloride

    ROCK inhibitor.

    ≥98%
  • H1862

    Heptaplatin

    Pt-based DNA cross-linker.

    ≥98%
  • B8144

    Bulleyaconitine A

    Found in Aconitum bulleyanum; voltage-gated Na+...

    ≥95%
  • S0048

    Salicin

    Alcoholic β-glucoside found in willow bark, sa...

    ≥98%